Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Diabeedi sümptomite küsimustik× | AGHDA: Täiskasvanute Kasvuhormooni Puudulikkuse Hindamine× | |
|---|---|---|
| Valdkond | Endokrinoloogia | Endokrinoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1994 | 2000 |
| Looja≠ | Peta Grootenhuis, Frans Snoek, Rolf Heine, Lex Bouter | Anthony Hunt, Garry Werther, Peter Wrightson |
| Tüüp≠ | Patient self-report symptom checklist | Patient self-report questionnaire |
| Algallikas≠ | Grootenhuis, P. A., Snoek, F. J., Heine, R. J., & Bouter, L. M. (1994). Development of a type 2 diabetes symptom checklist: A measure of symptom severity. Diabet Med, 11(3), 253-261. DOI ↗ | Hunt, A. E., Werther, G. A., & Wrightson, P. (2000). The utility of AGHDA in identifying GH-deficient adults. Clin Endocrinol (Oxf), 52(3), 341-346. link ↗ |
| Rööpnimetused | DSC-34 | AGHDA-25 |
| Seotud | 3 | 3 |
| Kokkuvõte≠ | The Diabetes Symptom Checklist is a 34-item patient-reported outcome measure assessing the frequency and burden of symptoms directly related to diabetes and its complications. Developed by Grootenhuis and colleagues in 1994, it captures eight symptom dimensions including hyperglycemic symptoms, hypoglycemic symptoms, fatigue, polyuria, neuropathic pain, and psychological distress. The instrument is used to quantify symptom experience and treatment response across diverse diabetes populations. | The AGHDA is a 25-item disease-specific quality of life questionnaire designed to assess the burden of adult growth hormone (GH) deficiency. Developed by Hunt, Werther, and colleagues in 2000, it evaluates symptoms and functional impairments directly related to GH deficiency, including fatigue, reduced muscle strength, weight gain, and psychological difficulties. The instrument is widely used in endocrinology practice and clinical trials to quantify the impact of GH replacement therapy. |
| ScholarGateAndmestik ↗ |
|
|